Gilead Sciences, Inc. cash flow to debt ratio of 40.18% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Gilead Sciences, Inc.'s free cash flow has decreased 8.24% from $10.30B last year to $9.46B, signaling decreasing performance

Gilead Sciences, Inc.'s debt to equity ratio is 0.21, which means that the company's assets are healthy financed, signaling financial stability.

Gilead Sciences, Inc.'s debt has decreased relative to shareholder equity from 1.38 last year to 0.21 today, signaling strengthened financials

Gilead Sciences, Inc. has a net debt to EBITDA ratio of 1.13x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Gilead Sciences, Inc.'s interest coverage ratio is -1.50, which means that the company struggles to meet interest obligations, signaling financial risk.

Gilead Sciences, Inc.'s profit margin has decreased (737.28%) in the last year from 1.67% to -10.64%, signaling decreasing performance

Gilead Sciences, Inc.'s short-term assets of $18.34B exceed its short-term liabilities of $11.81B

Gilead Sciences, Inc.'s return on assets of -6.56% is lower than the 5.00% threshold, indicating inefficient asset utilization

Gilead Sciences, Inc.'s return on equity of -16.30%, is lower than 15.00%, indicating bad performance

Gilead Sciences, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Gilead Sciences, Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Gilead Sciences, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Gilead Sciences, Inc. has a free cash flow yield of 5.72%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Gilead Sciences, Inc.'s yearly earnings has increased 1.67K% since last year from $480.00M to $8.51B, signaling increasing performance

Gilead Sciences, Inc.'s yearly revenue has increased 2.40% since last year from $28.75B to $29.44B, signaling increasing performance

ROIC -3.66% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Gilead Sciences, Inc.'s 3-year revenue CAGR of 2.57% is positive, indicating growing revenue over the past 3 years

Gilead Sciences, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Gilead Sciences, Inc. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Gilead Sciences, Inc. is overvalued relative to its fair value price of 95.07 based on Discounted Cash Flow model

Gilead Sciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Gilead Sciences, Inc. is overvalued relative to its fair value price of 47.31 based on EBITDA multiple model

Gilead Sciences, Inc. has an EV/EBITDA ratio of 13.29x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Gilead Sciences, Inc. is overvalued relative to its fair value price of 86.19 based on Earnings Fair Value model

Gilead Sciences, Inc. has insufficient data to calculate the PEG ratio.

Gilead Sciences, Inc. has a price-to-book ratio of 14.08x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Gilead Sciences, Inc. has a price-to-sales ratio of 5.43x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue